Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results

Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, Houchard A, Ruszniewski P (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S773-S773

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2020.08.1375

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Ipsen Pharma FR France (FR) Queen Elizabeth Hospital Birmingham GB United Kingdom (GB) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne FR France (FR) Hôpital Edouard Herriot FR France (FR) Charité - Universitätsmedizin Berlin DE Germany (DE) Cliniques universitaires Saint-Luc (CHU St-Luc) BE Belgium (BE) University of Warmia and Mazury in Olsztyn PL Poland (PL)

How to cite

APA:

Pavel, M.E., Cwikla, J.B., Lombard-Bohas, C., Borbath, I., Shah, T., Pape, U.-F.,... Ruszniewski, P. (2020). Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results. In ANNALS OF ONCOLOGY (pp. S773-S773). AMSTERDAM: ELSEVIER.

MLA:

Pavel, Marianne Ellen, et al. "Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results." Proceedings of the ESMO Virtual Congress AMSTERDAM: ELSEVIER, 2020. S773-S773.

BibTeX: Download